Literature DB >> 21402304

Predicting EQ-5D values using the SGRQ.

Helen J Starkie1, Andrew H Briggs, Mike G Chambers, Paul Jones.   

Abstract

OBJECTIVES: The purpose of this study was to develop and validate an algorithm that predicts EQ-5D utility from the St. George's Respiratory Questionnaire (SGRQ) in subjects with chronic obstructive pulmonary disease and to examine the effect of using this algorithm in predicting quality-adjusted life-years (QALYs).
METHODS: In the TORCH (Towards a Revolution in COPD Health) trial, the SGRQ and EQ-5D were administered at baseline and every 24 weeks for 3 years. To map EQ-5D utility from the SGRQ, ordinary least squares (OLS), generalized linear models (GLMs) and two-part models were used. Algorithms were developed in a fitting sample and used to predict utility scores in a validation sample and selected based on root-mean-square error (RMSE). QALYs were estimated from the algorithm and compared to QALYs derived from EQ-5D utility scores collected in the trial.
RESULTS: A simple OLS algorithm was found to perform as well as algorithms developed using more complex modeling structures. The resulting model was (RMSE 0.1723): EQ-5D = 0.9617 - 0.0013 × SGRQ total - 0.0001 × SGRQ total(2) + 0.0231 × male. Ordering of treatments by QALY gain was dependent on the method of utility estimation.
CONCLUSION: A mapping algorithm can be used to predict EQ-5D utility scores from the SGRQ and may be useful in some situations; however, for use in a health technology assessment (HTA) submission in which precision of estimation is important, it is in the interests of both the manufacturer and the HTA body that utility scores be directly derived from the clinical trial population.
Copyright © 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21402304     DOI: 10.1016/j.jval.2010.09.011

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  31 in total

Review 1.  A Review of Utility Measurement Methods Used in Pharmacoeconomic Submissions to HIRA in South Korea: Methodological Consistency and Areas for Improvement.

Authors:  Jihyung Hong; Eun-Young Bae
Journal:  Pharmacoeconomics       Date:  2021-07-28       Impact factor: 4.981

Review 2.  Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

Authors:  Iñigo Bermejo; Matt Stevenson; Katy Cooper; Sue Harnan; Jean Hamilton; Mark Clowes; Christopher Carroll; Tim Harrison; Shironjit Saha
Journal:  Pharmacoeconomics       Date:  2018-02       Impact factor: 4.981

3.  Cost-Effectiveness Of Once-Daily Single-Inhaler Triple Therapy In COPD: The IMPACT Trial.

Authors:  Afisi S Ismaila; Nancy Risebrough; Melanie Schroeder; Dhvani Shah; Alan Martin; Emma C Goodall; Kerigo Ndirangu; Gerard Criner; Mark Dransfield; David Mg Halpin; MeiLan K Han; David A Lomas
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-11-29

4.  Mapping the Haem-A-QoL to the EQ-5D-5L in patients with hemophilia.

Authors:  Richard Huan Xu; Dong Dong; Nan Luo; Eliza Lai-Yi Wong; Renchi Yang; Junshuai Liu; Huiqin Yuan; Shuyang Zhang
Journal:  Qual Life Res       Date:  2021-11-30       Impact factor: 4.147

5.  Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective.

Authors:  Melanie Schroeder; Nicole Benjamin; Laura Atienza; Chandroday Biswas; Alan Martin; John D Whalen; José Luis Izquierdo Alonso; Juan Antonio Riesco Miranda; Juan José Soler-Cataluña; Alicia Huerta; Afisi S Ismaila
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-07-10

6.  Can Technology-Based Physical Activity Programs for Chronic Obstructive Pulmonary Disease Be Cost-Effective?

Authors:  John P Ney; Stephanie A Robinson; Caroline R Richardson; Marilyn L Moy
Journal:  Telemed J E Health       Date:  2021-02-24       Impact factor: 3.536

7.  Cost-Effectiveness of Domiciliary High Flow Nasal Cannula Treatment in COPD Patients with Chronic Respiratory Failure.

Authors:  Sabrina Storgaard Sørensen; Line Hust Storgaard; Ulla Møller Weinreich
Journal:  Clinicoecon Outcomes Res       Date:  2021-06-18

8.  Improving clinical reality in chronic obstructive pulmonary disease economic modelling : development and validation of a micro-simulation approach.

Authors:  Yumi Asukai; Michael Baldwin; Tiago Fonseca; Alastair Gray; Laura Mungapen; David Price
Journal:  Pharmacoeconomics       Date:  2013-02       Impact factor: 4.981

9.  Protocol for a systematic review and economic evaluation of the clinical and cost-effectiveness of non-hospital-based non-invasive ventilation (NIV) in patients with stable end-stage COPD with hypercapnic respiratory failure.

Authors:  Chirag Dave; Alice Turner; Janine Dretzke; Sue Bayliss; Deirdre O'Brien; Sue Jowett; David Moore
Journal:  Syst Rev       Date:  2014-03-27

10.  Economic evaluation of aclidinium bromide in the management of moderate to severe COPD: an analysis over 5 years.

Authors:  Andreas Karabis; Michelle Mocarski; Indra Eijgelshoven; Gert Bergman
Journal:  Clinicoecon Outcomes Res       Date:  2014-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.